News | Naya Biosciences

top of page

Screenshot_2023-10-03_at_9.50.39-removebg-preview.png

NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 31st, 2024

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

October 24th, 2024

INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences

October 22nd, 2024

INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)

October 14th, 2024

Revolutionizing Healthcare: NAYA Biosciences' Vision for Oncology, Fertility & Regenerative Medicine (Jane King Interview With NAYA CEO Dr. Daniel Teper)

March 13th, 2024

How This New and Emerging Business Model Is Changing the Face of Biotech Today

February 12th, 2024

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)

January 23rd, 2024

INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors

January 17th, 2024

NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal

December 11th, 2023

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

December 6th, 2023

NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Merger

November 10th, 2023

Free Registration Is Now Open For Tribe Public's CEO and Q&A Presentation Webinar Event "Accelerating Biotech Value Creation" Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023

October 27th, 2023

INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company

October 23rd, 2023

INVO Closes Acquisition of Wisconsin Fertility Institute

August 11th, 2023

INVO Receives 510(k) FDA Clearance for Expanded Use of the INVOcell Device

June 27th, 2023

INVO Congratulates Wisconsin Fertility Institute on Being Named One of America's Best Fertility Clinics by Newsweek

Apri 5th, 2023

Dr. Sue Ellen Carpenter of INVO Bioscience's Atlanta-based INVO Center - Bloom Fertility - Named Top Doctor by Castle Connolly

September 22nd, 2022

New Birmingham INVO Center Offers Families an Affordable Advanced Fertility Treatment Solution to Help Combat Rising Costs

March 10th, 2022

INVO Bioscience Announces Official Opening of "Bloom Fertility, an INVO Center" in Atlanta

September 7th, 2021

INVO Bioscience Announces First Joint-Venture Grand Opening Scheduled for August 9, 2021 in Birmingham, Alabama

August 2nd, 2021

INVO Bioscience Signs Joint Venture Agreement with Bloom Fertility to Open an INVOcell Fertility Clinic in Atlanta

June 30th, 2021

bottom of page